Senzime AB (publ) (FRA:6YC)

Market Cap	74.62M +3.3%
Revenue (ttm)	8.11M +62.2%
Net Income	-10.91M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	80
Open	0.4320
Previous Close	0.4290
Day's Range	0.4215 - 0.4320
52-Week Range	0.3005 - 0.7500
Beta	n/a
RSI	45.60
Earnings Date	Feb 18, 2026

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also pr...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 54
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6YC

Financial Performance

In 2024, Senzime AB's revenue was 58.48 million, an increase of 63.55% compared to the previous year's 35.75 million. Losses were -118.73 million, -11.50% less than in 2023.

Financial numbers in SEK